LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

Home・Akcijų sąrašas・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

1.14 -5.79

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.12

Max

1.22

Pagrindiniai rodikliai
By Trading Economics
Pajamos	32M -8.3M
Pardavimai	-7.5M 37M
Pelnas, tenkantis vienai akcijai	-0.12
Pelno marža	-22.258
Darbuotojai	485
EBITDA	509K -38M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+87.4% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-60M 421M
Ankstesnė atidarymo kaina	6.93
Ankstesnė uždarymo kaina	1.14

Naujienos nuotaikos

By Acuity

50%

171 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

1.13 / N/A Palaikymas ir pasipriešinimas

Pacific Biosciences of California Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-14 22:44; UTC

Įsigijimai, susijungimai, perėmimai

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

2026-05-14 22:27; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

2026-05-14 22:12; UTC

Uždarbis

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

2026-05-14 21:52; UTC

Įsigijimai, susijungimai, perėmimai

LVMH to Sell Marc Jacobs

2026-05-15 00:00; UTC

Uždarbis

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

2026-05-14 23:57; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Stake Sales Aim to Secure Funds for Future Investments

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

2026-05-14 23:56; UTC

Rinkos pokalbiai

Gold Prices Rise on Strong Demand -- Market Talk

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

2026-05-14 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-14 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

2026-05-14 23:47; UTC

Uždarbis

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

2026-05-14 23:47; UTC

Uždarbis

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

2026-05-14 23:46; UTC

Uždarbis

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

2026-05-14 23:46; UTC

Uždarbis

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

2026-05-14 23:28; UTC

Rinkos pokalbiai

New Zealand's Economy Faltering Amid Shocks -- Market Talk

2026-05-14 23:00; UTC

Rinkos pokalbiai

Australia's One Nation Party Leads In The Polls -- Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Court Decision 'Negative But Balanced' for Coles -- Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-14 22:35; UTC

Rinkos pokalbiai

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

2026-05-14 22:11; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Agrees to Sell Marc Jacobs -- WSJ

2026-05-14 22:06; UTC

Rinkos pokalbiai

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

2026-05-14 22:00; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

2026-05-14 21:55; UTC

Uždarbis

Nu Holdings 1Q EPS 18c >NU

2026-05-14 21:55; UTC

Uždarbis

Nu Holdings 1Q Rev $4.97B >NU

Akcijų palyginimas

Kainos pokytis

Pacific Biosciences of California Inc Prognozė

Kainos tikslas

By TipRanks

87.4% į viršų

12 mėnesių prognozė

Vidutinis 2.38 USD 87.4%

Aukščiausias 3 USD

Žemiausias 1.5 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pacific Biosciences of California Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Pacific Biosciences of California Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.13 / N/APalaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Rinkos nuotaikos

By Acuity

171 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.